Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

Orasis Pharmaceuticals announced the appointment of Julie Speed as senior vice president (SVP), head of strategy and marketing. Ms. Speed brings over two decades of leadership in eye care and will be responsible for developing the brand strategy and building the marketing organization as we prepare for phase 3 readout and FDA submission for lead candidate, CSF-1.

“I am extremely excited to join Orasis Pharmaceuticals at such a pivotal time for the company as we execute on pre-commercialization activities," said Ms. Speed. "It is a privilege to join the team as we pioneer a solution that balances efficacy, safety and comfort for people with presbyopia."

Elad Kedar, chief executive officer of Orasis, added, “We are pleased to have Julie join the Orasis team at such a critical juncture for the company as we approach phase 3 readout. We look forward to leveraging her expertise across many brands to lead our strategy and build a strong marketing team, positioning us to be a front-runner in presbyopia.”

Ms. Speed brings over two decades of proven ophthalmic leadership across both pharmaceutical and medical device. Her expertise spans from commercial leadership positions at Alcon and Johnson & Johnson Vision-Surgical, progressing commercial strategy and brands, to start-up organizations at Eyevance and TearLab, building marketing strategy and teams from the ground up. Her broad marketing and launch experience with U.S. and global brands will help accelerate Orasis towards launch readiness. Ms. Speed earned her B.S. in Biomedical Science from Texas A&M University and MBA from Texas Christian University.